Expanded Access for DeltaRex-G for Advanced Solid Tumors, B Cell Lymphoma and Multiple Myeloma

Conditions:   Advanced Solid Tumors;   B Cell Lymphoma;   Multiple Myeloma Intervention:   Drug: DeltaRex-G Sponsor:   Aveni Foundation Temporarily not available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

We analyzed the outcomes of all-trans-retinoic acid (ATRA) and IV arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline induction therapy in 118 acute promyelocytic leukemia (APL) patients with high risk (HR) and standard risk (SR) from January 2008 to December 2017. The medical records of 118 APL patients (HR, n=45; SR, n=73) who received the frontline triple combination regimen at Henan Provincial People ’s Hospital and Tongji Hospital were retrospectively reviewed. Consolidation therapy comprised 6 cycles of ATO and ATRA plus IDA, and IDA was administered in 1∼4 cycles of consolidation therapy based on t...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Sankey plots were generated to illustrate the heterogeneity of treatment sequences and transitions over time in real-world patients from the Connect MM Registry.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Commentary Source Type: research
Conflicting reports exist on risk of infection with ibrutinib, We conducted a systematic review and meta-analysis of randomized controlled trials to estimate the relative risk, Ibrutinib use was associated with a statistically significant increased risk of infection in patients with B-cell malignancies, Patients on ibrutinib should be vigilantly monitored for development of infections
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Anemia is the most common cytopenia seen in the myelodysplastic syndromes (MDS). The majority of patients with MDS will require red blood cell (RBC) transfusions during the course of their disease. However, unlike many other disease groups, there is no consensus on the optimal strategy for RBC transfusion in this patient population. In this article, we review the data supporting the use of restrictive transfusion strategies in multiple patient populations and discuss the current literature regarding transfusion management in patients with MDS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Publication date: Available online 10 October 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Forat Lutfi, William Paul Skelton, Yu Wang, Emma Rosenau, Nosha Farhadfar, Hemant Murthy, Christopher R. Cogle, Ranadall Brown, John Hiemenz, John Hiemenz, John R. Wingard, Maxim NorkinAbstractObjective/BackgroundClinical predictors of delayed engraftment following autologous hematopoietic cell transplantation (AHCT) are poorly described in the literature. The purpose of this study was to identify pretransplant characteristics contributing to delayed engraftment (DE) following AHCT.MethodsA retrospective, single in...
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
CONCLUSIONThe majority of real-world RRMM patients were ineligible for hallmark RCTs. Eligibility rates varied across RCTs, underlining the flawed nature of cross-study comparisons without RCT validation. OS was significantly affected by inability to meet criteria highlighting limited generalizability of RCT results. Greater efforts should be made to broaden eligibility criteria to reflect real-world clinical characteristics to narrow the gap between RCT efficacy and observed effectiveness in real-world MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThese results support the claim that MRD status can be used as a surrogate for PFS in NDMM.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joseph MikhaelAbstractThe advent of new, more effective, and less toxic therapies has revolutionized the management of multiple myeloma in the past decade. Despite the availability of new treatments, the majority of patients with multiple myeloma will become refractory to the therapies that currently comprise the hematologic standard of care for the malignancy: proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Moreover, in recent years, a new subset of patients refractory to all 3 of these agen...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOutpatient ASCT is a safe and feasible treatment strategy with low TRM. Overall resource utilization are significantly lower than inpatient auto-transplantation: however, this requires a multidisciplinary approach with close follow up
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): James Yeung, Sebastiaan van Hal, P. Joy Ho
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Lymphoma | Myeloma | Research